

Effective Date: 7/1/2022
Reviewed: 8/2020, 4/2021, 3/2022, 6/2022, 4/2023, 3/2024
Scope: Medicaid

# **Belsomra (suvorexant), Dayvigo (lemborexant), Quviviq (daridorexant)**

## **I. CRITERIA FOR APPROVAL**

An authorization may be granted when all the following criteria are met:

- A. The member has a diagnosis of insomnia disorder as characterized by the DSM-V (difficulty with sleep onset or sleep maintenance), **AND**
- B. Member is at least 18 years of age, **AND**
- C. Potential factors contributing to sleep disturbances have been addressed or are currently being addressed (e.g., inappropriate sleep hygiene and sleep environment issues) as well as treatable medical/psychiatric disorders that are co-morbid with insomnia; **AND**
- D. Member meets one of the following:
  - 1. Member has experienced an inadequate treatment response, intolerance, or contraindication to at least three formulary alternatives (i.e., zolpidem, trazodone, temazepam, etc.),
  - 2. Member has a documented history of known substance use disorder and/or is receiving current treatment for addiction, in which case most formulary alternatives may be deemed inappropriate,
  - 3. Provider is a sleep specialist with appropriate reasoning and supporting documentation for not prescribing a formulary alternative
- E. If requesting Quviviq, member has also experienced an inadequate treatment response, intolerance, or contraindication to Dayvigo or Belsomra

## **II. CONTINUATION OF THERAPY**

Authorization of 12 months may be granted for all members who meet all initial criteria and who achieve and maintain positive clinical response after at least 6 months of therapy with Belsomra, Dayvigo, or Quviviq as evidenced by an improvement in sleep onset and/or sleep maintenance.

## **III. QUANTITY LIMIT**

- Belsomra, Dayvigo, Quviviq: 1 tablet per day

## **IV. COVERAGE DURATION**

- 12 months

## **V. REFERENCES**

1. Belsomra [package insert]. Whitehouse Station, New Jersey: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; February 2023.
2. Dayvigo [package insert]. Woodcliff Lake, New Jersey: Eisai; December 2023.
3. Quviviq [package insert]. Randor, Pennsylvania: Idorsia Pharmaceuticals US Inc.; November 2023.